Attovia Therapeutics Inc.
ATTO | NASDAQ
$21.30
-$0.84 (-3.79%)
At close: Sep 21, 2026, 4:00 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 |
|---|---|---|
Net Income | -60.9M | -45.05M |
Depreciation & Amortization | 804K | 313K |
Stock-Based Compensation | n/a | n/a |
Other Working Capital | 96K | -181K |
Other Non-Cash Items | 619K | 8.16M |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | 276K | 1.54M |
Operating Cash Flow | -59.2M | -35.04M |
Capital Expenditures | -2.31M | -1.77M |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -221.89M | -46.03M |
Sales Maturities Of Investments | 150.75M | 8M |
Other Investing Acitivies | n/a | n/a |
Investing Cash Flow | -73.46M | -39.8M |
Debt Repayment | n/a | -171K |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | n/a | n/a |
Financial Cash Flow | 142.01M | 82.75M |
Net Cash Flow | 9.56M | 30.63M |
Free Cash Flow | -61.51M | -36.81M |
Adj. Free Cash Flow | -61.51M | -36.81M |
Maintenance CapEx | n/a | -313K |
Growth CapEx | -2.31M | -1.46M |
Owner Earnings | -59.2M | -35.35M |
Add to Watchlist
Select watchlists to add or remove ATTO